CAESAREA, Israel, April 26, 2017 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ: DRIO), a leading global digital health company with mobile
health and big data solutions, today announced the launch of a
direct-to-consumer channel in the United
Kingdom. Following the success of the direct-to-consumer
channels in the U.S. and Australia, DarioHealth will leverage its
knowledge to provide new opportunities for the greater U.K.
diabetes community to analyze and personalize their treatment.
With this launch, DarioHealth proves its continued commitment to
the U.K. market as it expands market penetration, providing
consumers more accessibility to DarioHealth products. Until today,
DarioHealth was only available through pharmacies and diabetes
educators in the U.K. Now, consumers will have the opportunity to
receive personalized diabetes care via an online shopping
experience, and be enabled to monitor their health in a more
convenient way. DarioHealth will bring its expansive online digital
marketing efforts, while having a strong infrastructure and partner
in Advance Therapeutics (UK) Ltd., a U.K. wide distributor of
specialist medical devices for the treatment of diabetes.
Erez Raphael, Chairman and CEO of
DarioHealth, commented on the announcement, "DarioHealth has been
operating in the U.K. market for several years now and today's
announcement strengthens DarioHealth's commitment to the diabetes
community within the U.K. Our U.K. partner, Advanced Therapeutics,
has the flexibility to offer customers quick, reliable, and
friendly service, which will greatly benefit our customers.
Furthermore, they have over 11 years of experience in the diabetes
industry which is very important to us, as this demonstrates their
true understanding of our customers' needs."
John Hughes, Managing Director of
Advanced Therapeutics (UK) Ltd., said of the partnership, "We
couldn't be more delighted with today's announcement and we look
forward to our continued partnership with DarioHealth. DarioHealth
has a highly skilled and professional team and their approach will
yield great results. The Dario smart diabetes management system is
already well-received and trusted here in the U.K. as an
easy-to-use, accurate blood glucose monitor."
DarioHealth is the creator of the acclaimed Dario™ Blood Glucose
Monitoring System all-in-one blood glucose meter that is small
enough to fit in one's pocket or purse. Along with the proprietary
native smartphone app, consumers can track and monitor their blood
glucose levels with test strips in a simple manner, without
carrying an additional dedicated device or traditional diabetes
kit. This provides people with diabetes an unrivaled method for
self-diabetes management.
About Advanced Therapeutics (UK) Ltd.
Advanced Therapeutics (UK) Limited are a U.K. wide distributor
of specialist medical devices that meet real clinical needs,
simplify therapy and improve quality of life. Advanced Therapeutics
(UK) Limited are the exclusive UK distributor for Dario™, a product
range by DarioHealth built around a cloud based Diabetes Management
System. Dario is designed with convenience, efficiency and results
in mind, providing an excellent solution to diabetes management and
putting it in the palm of the user. These innovative products all
work to improve patient health, provide a flexibility of lifestyle
and achieve good clinical outcomes.
Advanced Therapeutics (UK) Ltd. provide high quality training
and support to diabetes teams and patients, having the flexibility
to be able to offer an efficient, reliable and yet friendly
service. The 24 hour technical support is provided by a U.K.
based team, with 24 hour clinical support offered where needed.
Advanced Therapeutics (UK) Ltd. take pride in their ethos of
working within the highest ethical and moral standards. For more
information visit http://www.atuk.ltd
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app gives
users an unrivaled method for self-diabetes management. DarioHealth
is headquartered in Caesarea,
Israel with a regional office in Burlington, Massachusetts. For more
information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company
states that it will bring its expansive digital marketing effort to
the U.K., that Advance Therapeutics (UK) Ltd. will greatly benefit
the Company's customers and that the Company's professional team
and approach will yield great results, it is using forward-looking
statements. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario™) may differ significantly from those
set forth in the forward-looking statements. The Company undertakes
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331
Advanced Therapeutics Contact
John Hughes
Managing Director
johnhughes@atuk.ltd
+44-1926-833-273
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-expands-global-presence-with-direct-to-consumer-launch-in-the-uk-300446049.html
SOURCE DarioHealth Corp.